Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chidamide”

238 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 238 results

Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Not applicableUnknownNCT05896813
What this trial is testing

CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Who this might be right for
Newly Diagnosed Peripheral T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04668690
What this trial is testing

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Who this might be right for
Peripheral T Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 193
Testing effectiveness (Phase 2)Study completedNCT03820596
What this trial is testing

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Who this might be right for
Safety and Efficacy
Huiqiang Huang 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05029141
What this trial is testing

New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaRefractory Acute LeukemiaRelapsed Adult AML
The First Affiliated Hospital of Soochow University 21
Testing effectiveness (Phase 2)Looking for participantsNCT06701357
What this trial is testing

CR-CHOP+X in Previously Untreated DEL

Who this might be right for
DLBCL
Ruijin Hospital 49
Testing effectiveness (Phase 2)Ended earlyNCT05141357
What this trial is testing

HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
HUYABIO International, LLC. 5
Testing effectiveness (Phase 2)UnknownNCT05370547
What this trial is testing

Chidamide Bridging for CAR-T Therapy

Who this might be right for
Non Hodgkin's Lymphoma
Chinese PLA General Hospital 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06516978
What this trial is testing

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 528
Not applicableNot Yet RecruitingNCT07521124
What this trial is testing

ABC Maintenance Therapy for AML

Who this might be right for
Acute Myeloid Leukemia (AML) in Remission
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 104
Testing effectiveness (Phase 2)Looking for participantsNCT06220487
What this trial is testing

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

Who this might be right for
Acute Lymphoblastic LeukemiaPhiladelphia ChromosomePhiladelphia-Positive ALL+2 more
Nanfang Hospital, Southern Medical University 67
Testing effectiveness (Phase 2)Looking for participantsNCT06151106
What this trial is testing

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaRefractory T-Cell Lymphoma
The First Affiliated Hospital of Xiamen University 33
Testing effectiveness (Phase 2)UnknownNCT02886559
What this trial is testing

Chidamide Plus DCAG for Relapsed/Refractory AML

Who this might be right for
AMLRelapse
Chinese PLA General Hospital 100
Testing effectiveness (Phase 2)UnknownNCT03373019
What this trial is testing

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
ChidamideLymphoma, B-CellLymphoma, Large B-Cell, Diffuse+13 more
Fudan University 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT03031262
What this trial is testing

Efficacy and Safety of Chidamide in CBF Leukemia

Who this might be right for
AML
Institute of Hematology & Blood Diseases Hospital, China 250
Testing effectiveness (Phase 2)Looking for participantsNCT07318831
What this trial is testing

Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

Who this might be right for
Neuroblastoma (NB)Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital 27
Testing effectiveness (Phase 2)Looking for participantsNCT05088226
What this trial is testing

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Who this might be right for
Peripheral Blood Stem Cell Transplantation
Chinese PLA General Hospital 50
Testing effectiveness (Phase 2)UnknownNCT02856997
What this trial is testing

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Who this might be right for
Peripheral T Cell Lymphoma
Yuankai Shi 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06757387
What this trial is testing

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Peking University Cancer Hospital & Institute 45
Testing effectiveness (Phase 2)UnknownNCT05129189
What this trial is testing

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

Who this might be right for
HIV Infections
Shanghai Public Health Clinical Center 15
Next Page